Canuc Provides Details of Santa Rosa Mine Sampling, Sonora, Mexico

Mar 28, 2017 11:03 am UTC| Business

VANCOUVER, British Columbia, March 28, 2017 -- Canuc Resources Corporation (“Canuc” or the “Company”) (TSX-V:CDA) is pleased to provide summary information, previously compiled, pertaining to work done by Santa Rosa...

Marrone Bio Innovations and Evogene Advance Novel Bacteria and Related Proteins Beyond Discovery into Insecticidal Product Development Phase

Mar 28, 2017 11:02 am UTC| Business

DAVIS, Calif. and REHOVOT, Israel, March 28, 2017 -- Marrone Bio Innovations Inc. (MBI), (NASDAQ:MBII), a leading global provider of bio-based pest management and plant health products, and Evogene Ltd. (NASDAQ:EVGN)...

Tonix Pharmaceuticals Enrolls First Participant in Military-Related PTSD Phase 3 Trial of FDA Breakthrough Therapy-Designated TNX-102 SL

Mar 28, 2017 11:02 am UTC| Business

NEW YORK, March 28, 2017 -- Tonix Pharmaceuticals Holding Corp. (Nasdaq:TNXP) (Tonix), a company that is developing innovative pharmaceutical products to address public health challenges, announced today that it has...

FactSet Reports Solid Revenue and Earnings Growth in Second Quarter 2017

Mar 28, 2017 11:02 am UTC| Business

NORWALK, Conn., March 28, 2017 -- FactSet (the “Company”) (NYSE:FDS) (NASDAQ:FDS), a global provider of integrated financial information, analytical applications, and industry-leading service, today announced its...

Skyharbour Signs Option Agreement with Azincourt Uranium to Option 70% of the East Preston Uranium Property for $3,500,000 in Project Consideration and 4,500,000 Shares

Mar 28, 2017 11:02 am UTC| Business

VANCOUVER, British Columbia, March 28, 2017 -- Skyharbour Resources Ltd.(TSX-V:SYH) (OTCQB:SYHBF) (Frankfurt:SC1P) (the “Company”), in conjunction with Preston Uranium Project partner Clean Commodities Corp. (“Clean...

Cara Therapeutics Announces Positive Top-Line Data From Part A of Phase 2/3 Trial of I.V. CR845 in Chronic Kidney Disease-Associated Pruritus

Mar 28, 2017 11:02 am UTC| Business

Met primary endpoint with 68% reduction in worst itching scores versus placebo after eight-week treatment period (p0.0019) Met secondary endpoint in quality of life domains versus placebo after...

XOMA to Present Preclinical Data from its PTH1R Monoclonal Antibodies Program at the American Association for Cancer Research Annual Meeting

Mar 28, 2017 11:02 am UTC| Business

BERKELEY, Calif., March 28, 2017 -- XOMA Corporation (Nasdaq:XOMA), a pioneer in the discovery and development of therapeutic antibodies, announced today the presentation of data from its PTH1R Monoclonal Antibodies...